**APPENDICES**

**Appendix A: IASLC International Staging Committee (at the time of conception of this article)**

Peter Goldstraw, Past Chair, Royal Brompton Hospital and Imperial College, London, United Kingdom; Ramón Rami-Porta, Chair, Hospital Universitari Mutua Terrassa, Terrassa, Spain; Hisao Asamura, Chair Elect, National Cancer Center, Tokyo, Japan; David Ball, Peter MacCallum Cancer Institute, Melbourne, Australia; David Beer, University of Michigan, Ann Arbor, Michigan; Elisabeth Brambilla, Centre Hospitalier Universitaire Albert Michallon, Grenoble, France; Vanessa Bolejack, Cancer Research And Biostatistics, Seattle, Washington; Paul Bunn, Ex Office, University of Colorado Cancer Center, Aurora, Colorado; Kari Chansky, Cancer Research And Biostatistics, Seattle, Washington; John Crowley, Cancer Research And Biostatistics, Seattle, Washington; Frank Detterbeck, Yale University, New Haven, Connecticut; Wilfried Eberhardt, University of Essen, Essen, Germany; John Edwards, Northern General Hospital, Sheffield, United Kingdom; Françoise Galateau-Sallé, Centre Hospitalier Universitaire, Caen, France; David Gandara, Ex Office, University of California Davis Cancer Center, Sacramento, California; Dorothy Giroux, Cancer Research And Biostatistics, Seattle, Washington; Fergus Gleeson, Churchil Hospital, Oxford, United Kingdom; Patti Groome, Queen’s Cancer Research Institute, Kingston, Ontario, Canada; James Huang, Memorial Sloan-Kettering Cancer Center, New York, New York; James Jett, Ex Office, National Jewish Health, Denver, Colorado; Catherine Kennedy, University of Sydney, Sydney, Australia; Jhingook Kim, Samsung Medical Center, Seoul, Korea; Haruhiko Kondo, Shizuoka Cancer Center, Shizuoka, Japan; Mark Krasnik, Gentofte Hospital, Copenhagen, Denmark; Diana Lowry, Cancer Research And Biostatistics, Seattle, Washington; Jan van Meerbeeck, University Hospital, Ghent, Belgium; Takashi Nakano, Hyogo College of Medicine, Hyogo, Japan; Andrew Nicholson, Royal Brompton Hospital, London, United Kingdom; Anna Nowak, University of Western Australia, Subiaco, Australia; Harvey Pass, Board Liaison, New York University, New York, New York; Michael Peake, Glenfield Hospital, Leicester, United Kingdom; Pieter Postmus, Free University Medical Center, Amsterdam, The Netherlands; Thomas Rice, Cleveland Clinic, Cleveland, Ohio; Kenneth Rosenzweig, Mount Sinai Hospital, New York, New York; Valerie Rusch, Memorial Sloan-Kettering Cancer Center, New York, New York; Nagahiro Saijo, National Cancer Center Hospital East, Chiba, Japan; Paul van Schil, Antwerp University Hospital, Edegem (Antwerp), Belgium; Jean-Paul Sculier, Institut Jules Bordet, Brussels, Belgium; Leslie Sobin, Armed Forces Institute of Pathology, Washington, DC; Charles Thomas, Oregon Health & Science University, Portland, Oregon; Charles F. Thomas Jr, Mayo Clinic, Rochester, Minnesota; William Travis, Memorial Sloan-Kettering Cancer Center, New York, New York; Ming Tsao, The Princess Margaret Hospital, Toronto, Ontario, Canada; Masahiro Tsuboi, Board Liaison, Kanagawa Cancer Center, Yokohama, Japan; Andrew Turrisi, Sinai Grace Hospital, Detroit, Michigan; Eric Valliéres, Swedish Cancer Institute, Seattle, Washington; Johan Vansteenkiste, University Hospitals, Leuven, Belgium; Hirokazu Watanabe, National Cancer Center Hospital, Tokyo, Japan; Yi-Iong Wu, Guangdong Provincial Peoples Hospital, Guangzhou, People’s Republic of China.

**Appendix B: International Mesothelioma Interest Group (IMIG) Board Members**

Steve Albelda, University of Pennsylvania, Philadelphia, Pennsylvania; Sam Armato, The University of Chicago Medical Center, Chicago, Illinois; Paul Baas, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Courtney Broaddus, University of California San Francisco, San Francisco, California; Dean Fennell, Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom; Rabab Gaafar, Cairo University, Cairo, Egypt; Marie-Claude Jaurand, Institut National de la Santé et de la Recherche Médicale, Paris, France; Hedy Kindler, The University of Chicago Medical Center, Chicago, Illinois; Sakari Knuutila, University of Helsinki, Helsinki, Finland; Steven Mutsaers, University of Western Australia, Perth, Australia; Luciano Mutti, Vercelli Hospital, Vercelli, Italy; Takashi Nakano, Hyogo College of Medicine, Hyogo, Japan; Harvey Pass, New York University, New York, New York; Bruce Robinson, University of Western Australia, Perth, Australia; Jeremy Steele, St Bartholomew’s Hospital, London, United Kingdom; Daniel Sterman, University of Pennsylvania, Philadelphia, Pennsylvania; Jim teWaterNaude, University of Cape Town, Cape Town, South Africa; Walter Weder, University Hospital Zurich, Zurich, Switzerland.

**Appendix C: Advisory Board of the IASLC Mesothelioma Domain**

Paul Baas, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Jeremy Erasmus, MD Anderson Cancer Center, Houston, Texas; Seiki Hasegawa, Hyogo College of Medicine, Hyogo, Japan; Kouki Inai, Hiroshima University Postgraduate School, Hiroshima, Japan; Kemp Kernstine, City of Hope, Duarte, California; Hedy Kindler, The University of Chicago Medical Center, Chicago, Illinois; Lee Krug, Memorial Sloan-Kettering Cancer Center, New York, New York; Kristiaan Nackaerts, University Hospitals, Leuven, Belgium; David Rice, M.D. Anderson Cancer Center, Houston, Texas.

**Appendix D: Participating Institutions**

A.K. Cangir, Ankara University School of Medicine, Ankara, Turkey; L. Spaggiari and P. Solli, European Institute of Oncology (IEO), Milan, Italy; J. P. van Meerbeeck and B. Hasan, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; D. Waller and A. Nakas, Glenfield Hospital, Leicester, United Kingdom; T. Kishimoto, Japan Labour, Health, and Welfare Organization Hospitals (Rosai Hospitals), Japan; D. Rice, M.D. Anderson Cancer Center, Houston, Texas; R. Flores and V. Rusch, Memorial Sloan-Kettering Cancer Center, New York, New York; F. Galateau-Salle, MESONAT Registry, CHU, Caen, France; H. I. Pass, NYU Langone Medical Center, New York, New York; A. Olario and E. Ruffini, University of Torino, Ospedale San Giovanni Battista, Torino, Italy; H. Hoffmann and T. Muley, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; M. de Perrot, Toronto General Hospital and Princess Margaret Hospital, Toronto, Canada; W. Weder, University Hospital, Zurich, Switzerland; F. Rea, University of Padova, Padova, Italy; B. McCaughan and C. Kennedy, University of Sydney (Strathfield Private Hospital Campus), Sydney, Australia.